282 related articles for article (PubMed ID: 14746625)
1. Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole.
Wingfield AB; Fernandez-Obregon AC; Wignall FS; Greer DL
Br J Dermatol; 2004 Jan; 150(1):119-26. PubMed ID: 14746625
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole.
Gupta AK; Adam P; Dlova N; Lynde CW; Hofstader S; Morar N; Aboobaker J; Summerbell RC
Pediatr Dermatol; 2001; 18(5):433-8. PubMed ID: 11737692
[TBL] [Abstract][Full Text] [Related]
3. Systemic antifungal therapy for tinea capitis in children.
Chen X; Jiang X; Yang M; González U; Lin X; Hua X; Xue S; Zhang M; Bennett C
Cochrane Database Syst Rev; 2016 May; 2016(5):CD004685. PubMed ID: 27169520
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
Gupta AK; Gregurek-Novak T
Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230
[TBL] [Abstract][Full Text] [Related]
5. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial.
Singh S; Chandra U; Anchan VN; Verma P; Tilak R
Br J Dermatol; 2020 Nov; 183(5):840-846. PubMed ID: 32538466
[TBL] [Abstract][Full Text] [Related]
6. Systemic antifungal therapy for tinea capitis in children.
González U; Seaton T; Bergus G; Jacobson J; Martínez-Monzón C
Cochrane Database Syst Rev; 2007 Oct; (4):CD004685. PubMed ID: 17943825
[TBL] [Abstract][Full Text] [Related]
7. [Tinea capitis. Therapeutic options in the post-griseofulvin era].
Möhrenschlager M; Korting HC; Seidl HP; Ring J; Abeck D
Hautarzt; 2002 Dec; 53(12):788-94. PubMed ID: 12444518
[TBL] [Abstract][Full Text] [Related]
8. Tinea capitis: an overview with emphasis on management.
Gupta AK; Hofstader SL; Adam P; Summerbell RC
Pediatr Dermatol; 1999; 16(3):171-89. PubMed ID: 10383772
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes for tinea capitis in a skin of color population.
Bhanusali D; Coley M; Silverberg JI; Alexis A; Silverberg NB
J Drugs Dermatol; 2012 Jul; 11(7):852-6. PubMed ID: 22777228
[TBL] [Abstract][Full Text] [Related]
10. Tinea capitis: a treatment update.
Roberts BJ; Friedlander SF
Pediatr Ann; 2005 Mar; 34(3):191-200. PubMed ID: 15792111
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for the management of tinea capitis in children.
Kakourou T; Uksal U;
Pediatr Dermatol; 2010; 27(3):226-8. PubMed ID: 20609140
[TBL] [Abstract][Full Text] [Related]
12. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis.
Arca E; Taştan HB; Akar A; Kurumlu Z; Gür AR
J Dermatolog Treat; 2002 Mar; 13(1):3-9. PubMed ID: 12006131
[TBL] [Abstract][Full Text] [Related]
13. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris.
del Palacio Hernandez A; López Gómez S; González Lastra F; Moreno Palancar P; Iglesias Díez L
Clin Exp Dermatol; 1990 May; 15(3):210-6. PubMed ID: 2194715
[TBL] [Abstract][Full Text] [Related]
14. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus.
Tausch I; Decroix J; Gwiezdzinski Z; Urbanowski S; Baran E; Ziarkiewicz M; Levy G; Del Palacio A
Int J Dermatol; 1998 Feb; 37(2):140-2. PubMed ID: 9542675
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections.
Hay RJ; Logan RA; Moore MK; Midgely G; Clayton YM
J Am Acad Dermatol; 1991 Feb; 24(2 Pt 1):243-6. PubMed ID: 2007669
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species.
Lipozencic J; Skerlev M; Orofino-Costa R; Zaitz VC; Horvath A; Chouela E; Romero G; Gourmala N; Paul C;
Br J Dermatol; 2002 May; 146(5):816-23. PubMed ID: 12000378
[TBL] [Abstract][Full Text] [Related]
17. Exploring treatment and antifungal resistance in an outbreak of tinea caused by Microsporum audouinii.
Johansen CD; Shen JJR; Astvad KMT; Jemec GBE; Christensen JJ; Saunte DML
Mycoses; 2024 Jul; 67(7):e13760. PubMed ID: 38943042
[TBL] [Abstract][Full Text] [Related]
18. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris.
Faergemann J; Mörk NJ; Haglund A; Odegård T
Br J Dermatol; 1997 Apr; 136(4):575-7. PubMed ID: 9155961
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
Gupta AK
Pharmacoeconomics; 1998 Feb; 13(2):243-56. PubMed ID: 10178650
[TBL] [Abstract][Full Text] [Related]
20. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis.
Cáceres-Ríos H; Rueda M; Ballona R; Bustamante B
J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):80-4. PubMed ID: 10607324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
